Despite the considerable progress achieved in the last 30 years, vomiting and, especially,
nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In …

Little information exists on the functional impact of effective antiemetic protection. In the
present study, the Functional Living Index—Emesis (FLIE), was used to assess patient …

In early clinical trials, the NK1 receptor antagonist, aprepitant (EMEND®) was shown to
improve the protection provided by the best available therapy (hereafter referred to as …

Importance The prevention of chemotherapy-induced nausea and vomiting has an important
role in the overall management of cancer treatment. Objective To evaluate whether adding …

Introduction: Chemotherapy-induced nausea and vomiting (CINV) is associated with a
significant deterioration in quality of life and is perceived by patients as a major adverse …

Purpose To update the American Society of Clinical Oncology (ASCO) guideline for
antiemetics in oncology. Methods A systematic review of the medical literature was …

This is a comment on" The oral neurokinin-1 antagonist aprepitant for the prevention of
chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind …

Purpose To update a key recommendation of the American Society of Clinical Oncology
antiemetic guideline. This update addresses the use of the oral combination of netupitant (a …

Nausea and vomiting are still considered to be two of the most troublesome adverse events
(AEs) for patients treated with antineoplastic therapy. To optimise the utility of available …

Purpose This review summarizes the recommendations for the prophylaxis of acute and
delayed nausea and vomiting induced by multiple-day chemotherapy, high-dose …